MR2034

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525795

CAS#: 57236-85-8

Description: MR2034 is a kappa-Opioid receptor agonist, stimulating hypothalamic-pituitary-adrenal axis.

Chemical Structure

img
MR2034
CAS# 57236-85-8
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 525795
Name: MR2034
CAS#: 57236-85-8
Chemical Formula: C19H29NO2
Exact Mass: 303.22
Molecular Weight: 303.446
Elemental Analysis: C, 75.21; H, 9.63; N, 4.62; O, 10.54

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MR2034; MR-2034; MR 2034;

IUPAC/Chemical Name: (2R,11R)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-[[(R)-tetrahydrofuran-2-yl]methyl]-2α,6α-methano-3-benzazocin-8-ol

InChi Key: CDBCMJWTAFNWGY-BVLYKOKCSA-N

InChi Code: InChI=1S/C19H29NO2/c1-13-7-8-20(12-17-4-3-9-22-17)18-10-15-5-6-16(21)11-19(13,15)14(18)2/h5-6,13-14,17-18,21H,3-4,7-12H2,1-2H3/t13?,14-,17+,18+,19?/m0/s1

SMILES Code: OC(C1)=CC=C2C13C(C)CCN(C[C@@H]4OCCC4)[C@]([C@@H]3C)([H])C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: MR2034 is a kappa-Opioid receptor agonist.
In vitro activity: Accordingly, MR-2034 stimulated hypothalamic CRH release in vitro in a concentration-dependent fashion and this effect was antagonized dose-dependently by MR-1452. Reference: J Neuroendocrinol. 1996 Aug;8(8):579-85. https://pubmed.ncbi.nlm.nih.gov/8866244/
In vivo activity: MR-2034 was given intravenously to catheterized, freely moving, male Sprague-Dawley rats and serial blood samples were collected for ACTH and corticosterone (B) measurements. We evaluated also the site of MR-2034 action on the HPA axis in vivo, after the administration of alpha-helical CRH9-41, a CRH receptor antagonist, on hypothalamic CRH, pituitary ACTH, and B release in vitro. MR-2034 increased plasma ACTH and B levels in a dose-related fashion and this effect was antagonized by the selective kappa-opioid receptor antagonist MR-1452. In the presence of alpha-helical CRH9-41, the responses of plasma ACTH and B to MR-2034 were blunted significantly, suggesting that this compound activates the HPA axis through a CRH-dependent mechanism. Reference: J Neuroendocrinol. 1996 Aug;8(8):579-85. https://pubmed.ncbi.nlm.nih.gov/8866244/

Preparing Stock Solutions

The following data is based on the product molecular weight 303.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: Calogero AE, Scaccianoce S, Burrello N, Nicolai R, Muscolo LA, Kling MA, Angelucci L, D'Agata R. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro. J Neuroendocrinol. 1996 Aug;8(8):579-85. PMID: 8866244.
In vitro protocol: Calogero AE, Scaccianoce S, Burrello N, Nicolai R, Muscolo LA, Kling MA, Angelucci L, D'Agata R. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro. J Neuroendocrinol. 1996 Aug;8(8):579-85. PMID: 8866244.
In vivo protocol: Calogero AE, Scaccianoce S, Burrello N, Nicolai R, Muscolo LA, Kling MA, Angelucci L, D'Agata R. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro. J Neuroendocrinol. 1996 Aug;8(8):579-85. PMID: 8866244.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23. PubMed PMID: 24071566.

2: Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology. 2003 Jun;28(6):1125-39. Epub 2003 Mar 5. PubMed PMID: 12637953.

3: Wentland MP, Ye Y, Cioffi CL, Lou R, Zhou Q, Xu G, Duan W, Dehnhardt CM, Sun X, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. J Med Chem. 2003 Feb 27;46(5):838-49. PubMed PMID: 12593663.

4: Broadbear JH, Negus SS, Butelman ER, de Costa BR, Woods JH. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl). 1994 Jul;115(3):311-9. PubMed PMID: 7871070.

5: Barg J, Nah SY, Levy R, Saya D, Vogel Z. Modulation of thymidine incorporation by kappa-opioid ligands in rat spinal cord-dorsal root ganglion co-cultures. Brain Res. 1993 Nov 26;629(1):109-14. PubMed PMID: 8287265.

6: Frenk H, Miller J, Johannessen JN, Mayer DJ. Spinal paralysis and catalepsy induced by intrathecal injection of opioid agonists. Pharmacol Biochem Behav. 1990 Jun;36(2):243-7. PubMed PMID: 2162542.

7: Clark JA, Liu L, Price M, Hersh B, Edelson M, Pasternak GW. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J Pharmacol Exp Ther. 1989 Nov;251(2):461-8. PubMed PMID: 2553920.

8: Verlinde C, De Ranter C. Assessment of the kappa-opioid activity of a series of 6,7-benzomorphans in the rabbit vas deferens. Eur J Pharmacol. 1988 Aug 9;153(1):83-7. PubMed PMID: 2850928.

9: Hayes AG, Skingle M, Tyers MB. Evaluation of the receptor selectivities of opioid drugs by investigating the block of their effect on urine output by beta-funaltrexamine. J Pharmacol Exp Ther. 1987 Mar;240(3):984-8. PubMed PMID: 3559988.

10: Abbott FV, Franklin KB, Libman RB. A dose-ratio comparison of mu and kappa agonists in formalin and thermal pain. Life Sci. 1986 Nov 24;39(21):2017-24. PubMed PMID: 3023775.

11: Iyengar S, Kim HS, Wood PL. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J Pharmacol Exp Ther. 1986 Aug;238(2):429-36. PubMed PMID: 3016237.

12: Chahl LA. Withdrawal responses of guinea-pig isolated ileum following brief exposure to opiates and opioid peptides. Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):387-92. PubMed PMID: 2430191.

13: Skingle M, Hayes AG, Tyers MB. Effects of opiates on urine output in the water-loaded rat and reversal by beta-funaltrexamine. Neuropeptides. 1985 Feb;5(4-6):433-6. PubMed PMID: 2987740.

14: Rourke JD, Shaw JS. Failure to demonstrate mu-isoreceptors. Neuropeptides. 1984 Dec;5(1-3):85-8. PubMed PMID: 6099520.

15: Johnson N, Pasternak GW. The binding to rat brain homogenates of Mr2034, a universal opiate. Life Sci. 1983 Sep 5;33(10):985-91. PubMed PMID: 6310291.

16: Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503-12. PubMed PMID: 6249436; PubMed Central PMCID: PMC2044269.